Pharmacyte Biotech Stock Analysis
| PMCB Stock | USD 0.74 0.04 5.71% |
IPO Date 17th of September 2010 | 200 Day MA 0.9706 | 50 Day MA 0.8675 | Beta 0.308 |
At present, PharmaCyte Biotech's Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Long Term Debt To Capitalization is expected to grow to 0.01, whereas Short and Long Term Debt Total is forecasted to decline to about 43.4 K. With a high degree of financial leverage come high-interest payments, which usually reduce PharmaCyte Biotech's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.007891 | Current Value 0.007496 | Quarterly Volatility 0.49216313 |
Given that PharmaCyte Biotech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which PharmaCyte Biotech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of PharmaCyte Biotech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, PharmaCyte Biotech is said to be less leveraged. If creditors hold a majority of PharmaCyte Biotech's assets, the Company is said to be highly leveraged.
At present, PharmaCyte Biotech's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 165.3 M, whereas Common Stock Total Equity is forecasted to decline to 173.71. . At present, PharmaCyte Biotech's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 0.28, whereas Price Earnings To Growth Ratio is forecasted to decline to (0). PharmaCyte Biotech is overvalued with Real Value of 0.7 and Hype Value of 0.74. The main objective of PharmaCyte Biotech stock analysis is to determine its intrinsic value, which is an estimate of what PharmaCyte Biotech is worth, separate from its market price. There are two main types of PharmaCyte Biotech's stock analysis: fundamental analysis and technical analysis.
The PharmaCyte Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and PharmaCyte Biotech's ongoing operational relationships across important fundamental and technical indicators.
PharmaCyte | Build AI portfolio with PharmaCyte Stock |
PharmaCyte Stock Analysis Notes
The company has price-to-book ratio of 0.21. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PharmaCyte Biotech recorded a loss per share of 1.11. The entity had not issued any dividends in recent years. The firm had 1:1550 split on the 12th of July 2021. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about PharmaCyte Biotech contact Joshua Silverman at 917 595 2850 or learn more at https://pharmacyte.com.PharmaCyte Biotech Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. PharmaCyte Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding PharmaCyte Biotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech has some characteristics of a very speculative penny stock | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| PharmaCyte Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Dow Update Is PharmaCyte Biotech Inc vulnerable to short sellers - Market Risk Summary Verified Trade Idea Suggestions - baoquankhu1.vn |
PharmaCyte Largest EPS Surprises
Earnings surprises can significantly impact PharmaCyte Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-03-15 | 2022-01-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2021-12-14 | 2021-10-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2022-12-14 | 2022-10-31 | -0.08 | -0.0914 | -0.0114 | 14 |
PharmaCyte Stock Institutional Investors
| Shares | Advisor Group Holdings, Inc. | 2025-06-30 | 305 | Covestor Ltd | 2025-06-30 | 275 | Park Square Financial Group, Llc | 2025-06-30 | 37.0 | Sachetta Llc | 2025-06-30 | 14.0 | Bfsg, Llc | 2025-06-30 | 5.0 | Goss Wealth Management Llc | 2025-06-30 | 2.0 | Koesten Hirschmann & Crabtree Inc | 2025-06-30 | 2.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 1.0 | Ifp Advisors, Llc | 2025-06-30 | 1.0 | Vanguard Group Inc | 2025-06-30 | 194.4 K | Geode Capital Management, Llc | 2025-06-30 | 126.6 K |
PharmaCyte Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.51 M.PharmaCyte Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.51 | 0.54 | |
| Return On Capital Employed | (0.08) | (0.08) | |
| Return On Assets | 0.50 | 0.53 | |
| Return On Equity | 0.68 | 1.06 |
Management Efficiency
PharmaCyte Biotech has return on total asset (ROA) of (0.0476) % which means that it has lost $0.0476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1768) %, meaning that it created substantial loss on money invested by shareholders. PharmaCyte Biotech's management efficiency ratios could be used to measure how well PharmaCyte Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At present, PharmaCyte Biotech's Return On Tangible Assets are projected to slightly grow based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.53, whereas Return On Capital Employed is forecasted to decline to (0.08). At present, PharmaCyte Biotech's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 39.6 M, whereas Total Current Assets are forecasted to decline to about 13 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.14 | 10.95 | |
| Tangible Book Value Per Share | 7.90 | 7.03 | |
| Enterprise Value Over EBITDA | (0.23) | (0.24) | |
| Price Book Value Ratio | 0.16 | 0.17 | |
| Enterprise Value Multiple | (0.23) | (0.24) | |
| Price Fair Value | 0.16 | 0.17 | |
| Enterprise Value | 30.1 M | 29.1 M |
PharmaCyte Biotech showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Technical Drivers
As of the 8th of February, PharmaCyte Biotech holds the Semi Deviation of 5.45, coefficient of variation of 22322.05, and Risk Adjusted Performance of 0.0128. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PharmaCyte Biotech, as well as the relationship between them.PharmaCyte Biotech Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in PharmaCyte Biotech price series with the more recent values given greater weights.
PharmaCyte Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PharmaCyte Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on PharmaCyte Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PharmaCyte Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
PharmaCyte Biotech Outstanding Bonds
PharmaCyte Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PharmaCyte Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PharmaCyte bonds can be classified according to their maturity, which is the date when PharmaCyte Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
PharmaCyte Biotech Predictive Daily Indicators
PharmaCyte Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PharmaCyte Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PharmaCyte Biotech Forecast Models
PharmaCyte Biotech's time-series forecasting models are one of many PharmaCyte Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PharmaCyte Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.PharmaCyte Biotech Bond Ratings
PharmaCyte Biotech financial ratings play a critical role in determining how much PharmaCyte Biotech have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for PharmaCyte Biotech's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (4.12) | Unlikely Manipulator | View |
PharmaCyte Biotech Debt to Cash Allocation
As PharmaCyte Biotech follows its natural business cycle, the capital allocation decisions will not magically go away. PharmaCyte Biotech's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
PharmaCyte Biotech currently holds 3.28 M in liabilities. PharmaCyte Biotech has a current ratio of 74.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about PharmaCyte Biotech's use of debt, we should always consider it together with its cash and equity.PharmaCyte Biotech Other Current Liab Over Time
PharmaCyte Biotech Assets Financed by Debt
The debt-to-assets ratio shows the degree to which PharmaCyte Biotech uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.PharmaCyte Biotech Debt Ratio | 0.75 |
PharmaCyte Biotech Corporate Bonds Issued
Most PharmaCyte bonds can be classified according to their maturity, which is the date when PharmaCyte Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
PharmaCyte Short Long Term Debt Total
Short Long Term Debt Total |
|
About PharmaCyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how PharmaCyte Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PharmaCyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as PharmaCyte Biotech. By using and applying PharmaCyte Stock analysis, traders can create a robust methodology for identifying PharmaCyte entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (151.13) | (143.57) | |
| Operating Profit Margin | (124.64) | (130.87) | |
| Net Loss | (118.27) | (124.19) | |
| Gross Profit Margin | 0.24 | 0.23 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding PharmaCyte Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
| All Next | Launch Module |
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |